PSYENCE BIOMEDICAL LTD. (PBMWW)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price

$0.03

Day

+26.32%

Close 2026-09-22.

The company

B. Business Overview The Company is a multi-asset, vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, with pharmaceutical-grade drug candidates manufactured through its investment in PsyLabs. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs and are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative care context.

From Item 1: B. Business Overview.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

• Harraden Circle Investments, LLC — $27.92K
• Polar Asset Management Partners Inc. — $16.64K
• MMCAP International Inc. SPC — $14.58K
• TORONTO DOMINION BANK — $12.07K
• Calamos Advisors LLC — $10.5K
• Saba Capital Management, L.P. — $7.24K
• Clear Street Group Inc. — $6.25K
• GOLDMAN SACHS GROUP INC — $4.86K

Recent filings

• 6-K — 2026-09-14
• EFFECT — 2026-09-01
• F-3 — 2026-08-26
• S-8 — 2026-08-26
• 6-K — 2026-08-06
• 20-F — 2026-06-22
• SCHEDULE 13G/A — 2026-06-10
• 6-K — 2026-06-05
• SCHEDULE 13D — 2026-06-03
• 6-K — 2026-04-23